News Release

Enterin and Parkinson’s UK announce research collaboration in Parkinson’s dementia

Philadelphia-based clinical-stage biopharmaceutical company has announced a collaboration with Parkinson’s Virtual Biotech on a new phase 2 trial to study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia

Business Announcement

Parkinson's UK

PHILADELPHIA, October 13, 2022 – ​Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia.  

In January 2022, Enterin announced statistically significant results from a randomized, placebo-controlled Phase 2b trial [KARMET] in 150 subjects with PD. In this study, a subset of those enrolled had PD-associated dementia. Patients treated with ENT-01 exhibited improvement in cognitive function compared with those receiving placebo. Statistically significant benefit was observed 6 weeks post treatment suggesting ENT-01 has potential to modify disease progression.  

“Our studies have demonstrated ENT-01’s clinical benefit across a range of PD related non-motor symptoms such as gastrointestinal dysfunction, dementia, psychosis, sleep architecture and circadian rhythm, all commonly associated with PD,” stated Denise Barbut, Enterin’s Co-Founder, President and CMO. 

The pathologic process in PD dementia (PDD) includes the presence of alpha-synuclein (αS) aggregates in the enteric nervous system (ENS) and central nervous system (CNS). Inhibiting αS aggregation in the ENS may reduce the continuing disease process in both the ENS and CNS and slow the progression of PD. ENT-01 is administered orally and acts locally on the ENS.  It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons. This effectively improves neural signaling between the gut and brain via the vagus nerve.

“Through the Parkinson’s Virtual Biotech, we’re very excited to be working with Enterin as they look to develop a potential new treatment for Parkinson’s related dementia,” said Arthur Roach, Director of Research at Parkinson’s UK. “Parkinson’s is the fastest growing neurological condition in the world and  currently there is no cure. The medications we have today can only treat and manage some of the more than 40 symptoms.

“Whilst Parkinson’s is more commonly associated with motor symptoms like tremor, our community has asked us to make new and better treatments for Parkinson’s dementia a priority. We are encouraged by the clinical results that Enterin’s work has produced to date and look forward to the upcoming clinical trial which will have sites in the UK as well as in America.” 

“Enterin is very grateful to partner with such a prestigious and well-respected organization,” said David McCullough, CEO of Enterin. “We have worked closely with Parkinson’s UK and their clinical advisors to design a clinical study to evaluate ENT-01 in PD dementia. It is our hope that we can offer a new therapeutic option for these patients.” 


For more information, please contact: 

About Enterin Inc.

Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community’s understanding of the link between infections, dysfunction of the ENS and the onset and progression of neurodegenerative disease. Enterin’s lead compound, ENT-01, displaces membrane-bound αS aggregates from nerve cells in the ENS and improves neural signalling between the gut and the brain The second compound, ENT-03, increases insulin sensitivity by acting at the level of the brain and acutely normalizes blood sugar in diabetic mice. ENT-03 is being developed for the treatment of diabetes, obesity and Alzheimer’s Disease. Studies in humans will begin in Q1 2023. 

For more information, please visit ​

About Parkinson’s and Parkinson’s UK 

Parkinson’s is the fastest growing neurological condition in the world. Around 145,000 people in the UK have Parkinson’s.

We are Parkinson's UK. Here for everyone affected by the condition. Funding research into the most promising treatments, taking us closer to a cure every day. Fighting for fair treatment and better services.

Read more facts and statistics.

Further information, advice and support is available on our website, or our free, confidential helpline on 0808 800 0303.

About the Parkinson’s Virtual Biotech

A groundbreaking approach to deliver life-changing new treatments in years not decades.

Like other biotechs, the Parkinson’s Virtual Biotech uses cutting edge biological and chemical research to come up with new treatments. But it’s driven by people with Parkinson’s, not profit. Collaborative and agile, it adapts successful methods from the business world to deliver new treatments faster. 

Founded by Parkinson’s UK in 2017, the Parkinson’s Virtual Biotech is now an international programme in partnership with the Parkinson’s Foundation. We believe we’ll get to a cure faster by collaborating, not competing. 

To find out more, visit

Parkinson’s UK and the Parkinson’s Virtual Biotech: 

Emma Smith / 

Enterin Inc:

Katherine Wolf 


Lee Roth / Julia Weilman

Burns McClellan / 


Selina Husain / Robert Flamm, Ph.D.

Burns McClellan /


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.